ENTRY       D05775                      Drug
NAME        Rufinamide (JAN/USP/INN);
            Banzel (TN)
PRODUCT     BANZEL (Eisai)
  GENERIC   RUFINAMIDE (Ascend Laboratories)
            RUFINAMIDE (Aurobindo Pharma Limited)
            RUFINAMIDE (Aurobindo Pharma Limited)
            RUFINAMIDE (Bionpharma)
            RUFINAMIDE (Camber Pharmaceuticals)
            RUFINAMIDE (Glasshouse Pharmaceuticals Limited Canada)
            RUFINAMIDE (Glenmark Pharmaceuticals)
            RUFINAMIDE (Hikma Pharmaceuticals USA)
            RUFINAMIDE (Hikma Pharmaceuticals USA)
            RUFINAMIDE (Lupin Pharmaceuticals)
            RUFINAMIDE (Lupin Pharmaceuticals)
            RUFINAMIDE (Micro Labs Limited)
            RUFINAMIDE (Mylan Pharmaceuticals)
FORMULA     C10H8F2N4O
EXACT_MASS  238.0666
MOL_WEIGHT  238.1935
CLASS       Neuropsychiatric agent
             DG03199  Antiepileptic agent
              DG02034  Carboxamide antiepileptic
            Metabolizing enzyme substrate
             DG02970  CES substrate
REMARK      Therapeutic category: 1139
            ATC code: N03AF03
            Product: D05775<JP/US>
EFFICACY    Antiepileptic
  DISEASE   Lennox-Gastaut syndrome [DS:H01813]
COMMENT     Carboxamide derivative
TARGET      SCN1A [HSA:6323] [KO:K04833]
            SCN2A [HSA:6326] [KO:K04834]
            SCN3A [HSA:6328] [KO:K04836]
            SCN4A [HSA:6329] [KO:K04837]
            SCN5A [HSA:6331] [KO:K04838]
            SCN8A [HSA:6334] [KO:K04840]
            SCN9A [HSA:6335] [KO:K04841]
            SCN10A [HSA:6336] [KO:K04842]
            SCN11A [HSA:11280] [KO:K04843]
  PATHWAY   hsa04728(6323)  Dopaminergic synapse
METABOLISM  Enzyme: CES [HSA:1066 8824 23491 221223]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N03 ANTIEPILEPTICS
               N03A ANTIEPILEPTICS
                N03AF Carboxamide derivatives
                 N03AF03 Rufinamide
                  D05775  Rufinamide (JAN/USP/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Anticonvulsants
              Sodium Channel Agents
               Rufinamide
                D05775  Rufinamide (JAN/USP/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             1  Agents affecting nervous system and sensory organs
              11  Agents affecting central nervous system
               113  Antiepileptics
                1139  Others
                 D05775  Rufinamide (JAN/USP/INN)
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG03199  Antiepileptic agent
               DG02034  Carboxamide antiepileptic
                D05775  Rufinamide
             Metabolizing enzyme substrate
              DG02970  CES substrate
               D05775  Rufinamide
            Drug classes [BR:br08332]
             Neuropsychiatric agent
              DG03199  Antiepileptic agent
               D05775  Rufinamide
            Target-based classification of drugs [BR:br08310]
             Ion channels
              Voltage-gated ion channels
               Sodium channels
                SCN1A
                 D05775  Rufinamide (JAN/USP/INN) &lt;JP/US&gt;
                SCN2A
                 D05775  Rufinamide (JAN/USP/INN) &lt;JP/US&gt;
                SCN3A
                 D05775  Rufinamide (JAN/USP/INN) &lt;JP/US&gt;
                SCN4A
                 D05775  Rufinamide (JAN/USP/INN) &lt;JP/US&gt;
                SCN5A
                 D05775  Rufinamide (JAN/USP/INN) &lt;JP/US&gt;
                SCN8A
                 D05775  Rufinamide (JAN/USP/INN) &lt;JP/US&gt;
                SCN9A
                 D05775  Rufinamide (JAN/USP/INN) &lt;JP/US&gt;
                SCN10A
                 D05775  Rufinamide (JAN/USP/INN) &lt;JP/US&gt;
                SCN11A
                 D05775  Rufinamide (JAN/USP/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D05775
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D05775
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D05775
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D05775
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D05775
DBLINKS     CAS: 106308-44-5
            PubChem: 47207436
            LigandBox: D05775
            NIKKAJI: J575.180B
ATOM        17
            1   C8x C    27.5379  -17.1661
            2   C8x C    27.5379  -18.5624
            3   C8x C    28.7471  -19.2605
            4   C8y C    29.9564  -18.5624
            5   C8y C    29.9564  -17.1661
            6   C8y C    28.7471  -16.4679
            7   X   F    28.7471  -15.0718
            8   X   F    31.1843  -19.2715
            9   C1b C    31.1843  -16.4570
            10  N4y N    32.3863  -17.1508
            11  N5x N    32.4321  -18.5562
            12  N5x N    33.7844  -18.9475
            13  C8y C    34.5745  -17.7822
            14  C8x C    33.7104  -16.6707
            15  C5a C    35.9312  -17.8076
            16  N1a N    36.5583  -19.0940
            17  O5a O    36.6991  -16.6707
BOND        18
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     6   7 1
            8     4   8 1
            9     5   9 1
            10    9  10 1
            11   10  11 1
            12   11  12 2
            13   12  13 1
            14   13  14 2
            15   10  14 1
            16   13  15 1
            17   15  16 1
            18   15  17 2
///
